ArticleScientific reports2025
Real-world assessment of thromboembolic risk associated with tamoxifen.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of probiotic/synbiotic supplementation for osteoporosis: a meta-analysis of randomized controlled trials.Frontiers in medicine · 2026Pooled it
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- Acute Portal Vein Thrombosis Associated With Anastrozole Therapy: A Report of a Rare Case.Cureus · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Incidental Ovarian Vein Thrombosis During Breast Cancer Therapy With Tamoxifen and Trastuzumab.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been confirmed that tamoxifen (TAM) use is associated with thromboembolic risks; however, it remains uncertain which specific thromboembolic events warrant prioritized surveillance beyond those already listed in the prescribing information. This study was conducted to assess the relationship between TAM use and reported thromboembolic events using the latest FDA Adverse Event Reporting System (FAERS) data. Tamoxifen-related AEs reported in FAERS between January 2004 and December 2024 were extracted, screened for thromboembolic cases, and subjected to disproportionality analysis to identify significant signals. A clinical prioritization scoring system was then applied to rank signal relevance, and multivariate regression analyses were performed to identify factors associated with thromboembolic outcomes. Among 385 TAM-associated thromboembolic events, 28 significant signals were detected. Newly detected signals comprised unilateral paralysis, retinal artery occlusion, and atrial thrombosis. Male sex, older age, and elevated body mass were identified as risk indicators for thromboembolism. These findings may inform enhanced clinical surveillance and TAM risk stratification; however, further validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.